Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission

Author: Carella Angelo   Lerma Enrica  

Publisher: Springer Publishing Company

ISSN: 0939-5555

Source: Annals of Hematology, Vol.86, Iss.10, 2007-10, pp. : 749-752

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract